MDM2 and chronic myelogenous leukemia, BCR-ABL1 positive: Although no detailed studies on MDM2 expression in CML have been reported, it is known that overexpression of MDM2 is observed in 20 to 30% of patients with ALL [28]-[30] and is found to be associated with early treatment failure and a poor prognosis [31]–[34].